pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

InSilico Medicine

updated 5mo ago
community read0 votes
pipeline
4
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0

Pipeline(4)

pipeline depth4 products
Preclinical: 1Phase 1: 2Phase 2: 1
1Preclinical2Phase 11Phase 2
Phase 2
rentosertib acetate
Idiopathic Pulmonary Fibrosis
Phase 1
ISM-3412
Solid Tumor
Phase 1
ISM-6331
Malignant Mesothelioma
Preclinical
ISM-9274
Solid Tumor

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

nothing in the last 90 days
view all catalysts →
🐶 Hiring Signal
No open roles indexed yet — view InSilico Medicine jobs →

News

  • Menarini's Stemline picks up Georgiamune preclinical cancer immunotherapy in $1.1B deal
    Georgiamune, an immunology-focused biotech out of Maryland, has licensed a preclinical cancer drug candidate to Stemline Therapeutics, owned by Italy's Menarini Group, for up to $1.1 billion.
    fiercebiotech · 26d ago
  • Lilly partners with Hong Kong's Metis in $1.1B deal to bolster AI nanoparticle discovery
    The collaboration is another in a series of partnerships Lilly has accumulated in both drug delivery and AI-based technologies.
    fiercebiotech · 29d ago
  • Cerevance Parkinson’s drug shortens 'off time' in Ph. 3, paving path to FDA
    The Takeda spinout showed that a high dose of solengepras can shorten the periods during which difficult Parkinson’s disease symptoms like involuntary movements and sleepiness.
    biospace · 1mo ago
  • Lilly’s latest China drug deal; Immunovant’s setback in lupus
    Lilly wagered up to $3.35 billion in its fourth China-focused alliance since January 2025. Elsewhere, analysts are now more confident about one of Vertex’s top prospects and an RNA drug succeeded a…
    biopharma_dive · 1mo ago
  • Deep Dive: How AI is now essential in biopharma
    As Big Pharma adds AI technology to bolster drug development, a cadre of new, upstart biotechs are pushing drug discovery to new heights.
    biospace · 1mo ago
  • Novo looks to Anthropic’s AI models to ‘supercharge’ drug development
    The Danish drugmaker will use Claude Science as part of a goal to become "the world’s most AI-driven healthcare company."
    biopharma_dive · 2mo ago
  • Owkin, Servier ink oncology R&D deal to guide discovery and trial design
    AI drug discovery company Owkin has signed a pact with French drugmaker Servier to license Owkin’s AI scientist K Pro across Servier’s oncology discovery and trial operations.
    fiercebiotech · 2mo ago
  • Reeling from past failures, Parkinson's pipeline enters 'era of diversification'
    While some drugmakers continue to walk the alpha-synuclein antibody path, others like AC Immune opt for new approaches that could bring the first-ever disease-modifying therapy for Parkinson's dise…
    biospace · 2mo ago
  • China poses increasing security risk as US biotech innovation edge erodes
    The U.S. is scrambling to compete with a strategically positioned China on the biotech stage as the Asian country surpasses America in biomedical research and clinical trials. So far, China is winn…
    biospace · 2mo ago
  • Research into protein interactions sheds new light on causes of autism
    Studying protein-protein interactions might hold the key to identifying druggable targets for autism, a group of scientists at the University of California, San Francisco has suggested.
    fiercebiotech · 2mo ago
view all news mentions →
identifiers
source
globaldata
top tags
Oncology3Pulmonary Fibrosis1Pulmonology1
mentioned in
10news items
entity-linker matched

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?